- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01271842
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study (RESPIFLU)
Influenza A (H1N1) v2009 infection was responsible throughout the world of viral pneumonia and severe pulmonary edema requiring rescue therapeutics such as extracorporeal oxygenation. To date, no data exist on the outcome of patients having developed acute respiratory distress syndrome (ARDS) due to influenza A (H1N1) v2009, and in particular in patients with very severe lung injury requiring extracorporeal oxygenation. Although data exist on long-term outcome of survivors of ARDS, the patients included in the observational studies were heterogeneous with various underlying disease. Moreover, no study compared the outcome of survivors of ARDS according to the need or not of extracorporeal oxygenation. We therefore conducted this prospective case-control study to compare the long term pulmonary and extra pulmonary function in 2 groups of patients, one with severe ARDS due to H1N1 requiring extracorporeal oxygenation (case), and the second with ARDS due to H1N1 but without need for extracorporeal oxygenation (control). Eighteen case patients with inclusion and without non-inclusion criteria were selected from our national registry, and 32 controls (with inclusion and exclusion criteria) were matched on age, sex, and body mass index. All 48 patients will be contacted and asked to participate. Patients will be evaluate at least 9 months after ICU discharge, looking for health-related quality of life, measured by the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36), post traumatic stress disorder, assessed by the Impact of Event Scale Anxiety, and depression, assessed by the Hospital and Depression Score. Pulmonary function testing, including VO2 max test on a static bike will be performed. Muscle weakness will be clinically evaluated by the medical council research (MRC) test, with an additional electromyography if the result of the test was <48/60. A CT-scan will be performed, looking for lung abnormalities (fibrosis...). Albumin and prealbumin will be measured to evaluate the nutritional status.
Primary outcome measurement is carbon monoxide diffusion capacity. The primary hypothesis is that patients with extracorporeal oxygenation will have a carbon monoxide diffusion capacity lower than patients without extracorporeal oxygenation (15% difference between groups). Inclusion of 13 patients in the case group and 26 patients in the control group will allow testing this hypothesis with a statistical power of 80% (standard deviation 15%). Secondary outcome measures will be the quality of life, the presence or not of post-traumatic stress disorders, of anxiety and/or depression, the results of pulmonary function testing, of the CT-scan, and of muscle testing. All results will be compared in patients with and without extracorporeal oxygenation.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- CHU Pitié-Salpêtrière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients from 18 to 65 year-old
- Survivors of ARDS due to influenza A (H1N1) v2009 infection developed during the winter 2009-2010
- Influenza A (H1N1) infection confirmed by RT-PCR
- Written consent
- Need or not for extra corporeal lung oxygenation
Exclusion Criteria:
- Pre existing pulmonary disease
- Asthma
- Diabetes mellitus
- Immunodepression
- Cancer
- Severe obesity (BMI >35 kg/m²)
- Neuromuscular disease
- Pre existing cardiac disease
- Chronic renal failure
- Liver failure
- Stroke
- Pregnancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Extra corporeal oxygenation
Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
|
|
No extracorporeal oxygenation
Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Carbon monoxide diffusion capacity
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Health-related quality of life
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
|
Pulmonary function testing
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
|
Post traumatic stress disorder
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
|
Anxiety and depression
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
|
Muscle weakness
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
|
Lung abnormalities on CT scan
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
|
Alveoli-arterial gradient of oxygen during effort
Time Frame: At least 9 months after ICU discharge
|
At least 9 months after ICU discharge
|
Collaborators and Investigators
Investigators
- Principal Investigator: Charles-Edouard Luyt, MD, Assistance Publique - Hopitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Trauma and Stressor Related Disorders
- Mental Disorders
- Pathologic Processes
- Respiratory Tract Infections
- Infections
- Orthomyxoviridae Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia
- Lung Diseases, Interstitial
- Fibrosis
- Stress Disorders, Traumatic
- Pathological Conditions, Signs and Symptoms
- Influenza, Human
- Pulmonary Fibrosis
- Pneumonia, Viral
- Combat Disorders
Other Study ID Numbers
- C10-26
- 2010-A00741-38 (Registry Identifier: IDRCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Ziekenhuis Oost-LimburgRecruitingQuality of Life | Postoperative Quality of Recovery | Health-Related Quality-of-LifeBelgium
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Istituto Ortopedico RizzoliUniversity of BolognaCompletedImprove Quality of LifeItaly
-
Children's National Research InstituteCompletedProfessional Quality of LifeUnited States
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
-
Institute of Oncology LjubljanaUnknownHealth-related Quality of LifeSlovenia
-
Oslo University HospitalNorwegian Fund for Postgraduate Training in PhysiotherapyCompletedHealth-Related Quality of LifeNorway